Local

ABC-HCC
A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus trans arterial Chemoembolization (TACE) in intermediate-stage
HCC

IMMUWIN
A phase II study of immunotherapy with Durvalumab (MEDI4736) and Tremelimumab in combination with either Y-90
SIRT or TACE for intermediate stage HCC with pick-the-winner design

Zweit- und Drittlinientherapie

Bemara

Bemarituzumab in patients with FGFR2b-positive, advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed at least one prior line of palliative chemotherapy

Adjuvant

FIRE-9 / PORT

Prospective, randomized, open-multicenter Phase III to investigate the efficacy of active post-resection/ablation therapy in patients with metastatic colorectal cancer, R0/R1 reseziert

Erstlinientherapie

MOUNTAINEER-03 (SGNTUC-029)

An open label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-Line Treatment for Subjects with HER2+ Metastatic Colorectal cancer

Lokal

IMMUWHY

A phase II study of immunotherapy with durvalumab (MEDI4736) or durvalumab and tremelimumab, both combined with Y-90 SIRT therapy in patients with advanced stage intrahepatic biliary tract cancer (BTC) scheduled to receive Y-90 SIRT therapy as standard of care

Acticca-2

Radiofrequency ablation via catheter and  transpapillary access  in patients with cholangiocarcinoma (ACTICCA-2 trial) . A randomized, open-label investigator-initiated trial

Clean-Duct/ TRITICC-3

Phase IIa, prospective, single arm, open label, non-randomized, multi-center pilot study of durvalumab (MEDI4736) + intraductal radiofrequency ablation (ID-RFA) in extrahepatic cholangiocarcinoma

Erstlinientherapie

TRAP-BTC

Efficacy and safety of GemCis plus Trastuzumab plus Pembrolizumab in previously untreated HER2-positive biliary tract cancer

JZP598-302

An open-label randomized trial of the efficacy and safety of Zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer

Zweitlinientherapie

TT420C2308

A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma

Erstlinientherapie

Prism

A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy vs. Placebo and Chemotherapy in Patients with Treatment-naïve metastatic Pancreatic ductal Adenocarcinoma

Drittlinentherapie

SORATRAM

Cross-institutional, prospective, open label, single group basket study of combined CRAF and MEK inhibition in advanced-stage malignancies harboring BRAF mutations with impaired kinase activity Trametinib+Sorafenib